PRWeb:  The Miami-based firm, Greenberg Traurig is playing financial advisor to Valeant Pharmaceuticals in a merger deal with Biovail.  The deal is valued at $3.3 billion.  The definitive merger agreement was announced today and the Greenberg advisory team will be led by David Schwartzbaum and Michael Helsel.  Both attorneys are shareholders in the firm’s New York City office and have extensive experience in corporate governance matters.  In fact, Schwartzbaum is the co-chair of the firm’s Global Mergers and Acquisitions committee.

Greenberg Traurig, LLP is an international, full-service law firm with approximately 1775 attorneys serving clients from more than 30 offices in the United States, Europe and Asia. In the U.K., the firm operates as Greenberg Traurig Maher LLP.